Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 3, 2010, Pages 222-238

  Tsai, Hsing Ju ^a   Hwang, Sung Hee ^a   Morisseau, Christophe ^a   Yang, Jun ^a   Jones, Paul D ^a   Kasagami, Takeo ^a   Kim, In Hae ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioavailability; Cardiovascular diseases; Epoxyeicosatrienoic acids; Inflammation; Pharmacokinetics; Soluble epoxide hydrolase inhibitor

Indexed keywords

1 (1 METHYLSULFONYL PIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXYPHENYL)UREA; 1 ADAMANTAN 1 YL 3 [5 [2 (2 ETHOXYETHOXY)ETHOXY]PENTYL]UREA; 1 CYCLOHEPTYL 3 (1 ACETYLPIPERIDIN 4 YL)UREA; 1 TRIFLUOROMETHOXYPHENYL 3 (1 ACETYLPIPERIDIN 4 YL)UREA; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; 4 (3 ADAMANTAN 1 YL UREIDO) 2 HYDROXYL BENZOIC ACID METHYL ESTER; 4 [4 (3 ADAMANTAN 1 YL UREIDO) CYCLOHEXYLOXY]BENZOIC ACID; 4 [4 (3 TRIFLUOROMETHOXYPHENYL 1 UREIDO) CYCLOHEXYLOXY]BENZOIC ACID; HYDROLASE INHIBITOR; N (1 ACETYLPIPERIDIN 4 YL) N' (ADAMANT 1 YL)UREA; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; IC 50; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BENZOIC ACIDS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FEMALE; INHIBITORY CONCENTRATION 50; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 77953024076     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.03.018     Document Type: Article

References (62)

1. Ai D., Fu Y., Guo D., Tanaka H., Wang N., Tang C., Hammock B.D., Shyy J.Y., Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9018-9023.
2. Borhan B., Mebrahtu T., Nazarian S., Kurth M.J., Hammock B.D. Improved radiolabeled substrates for soluble epoxide hydrolase. Anal. Biochem. 1995, 231:188-200.
3. Chiamvimonvat N., Ho C.M., Tsai H.J., Hammock B.D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 2007, 50:225-237.
4. Dingemanse J., Appel-Dingemanse S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin. Pharmacokinet. 2007, 46:713-737.
5. Dorrance A.M., Rupp N., Pollock D.M., Newman J.W., Hammock B.D., Imig J.D. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 2005, 46:842-848.
6. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 2007, 82:60-67.
7. Frick O.L., Teuber S.S., Buchanan B.B., Morigasaki S., Umetsu D.T. Allergen immunotherapy with heat-killed Listeria monocytogenes alleviates peanut and food-induced anaphylaxis in dogs. Allergy 2005, 60:243-250.
8. Gauthier K.M., Yang W., Gross G.J., Campbell W.B. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. J. Cardiovasc. Pharmacol. 2007, 50:601-608.
9. Ghosh S., Chiang P.C., Wahlstrom J.L., Fujiwara H., Selbo J.G., Roberds S.L. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol. 2008, 102:453-458.
10. Gomez G.A., Morisseau C., Hammock B.D., Christianson D.W. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci. 2006, 15:58-64.
11. Granero G.E., Amidon G.L. Possibility of enterohepatic recycling of ketoprofen in dogs. Int. J. Pharm. 2008, 349:166-171.
12. Harris T.R., Li N., Chiamvimonvat N., Hammock B.D. The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy. Congest Heart Fail. 2008, 14:219-224.
13. Huang H., Morisseau C., Wang J., Yang T., Falck J.R., Hammock B.D., Wang M.H. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. Renal Physiol. 2007, 293:F342-349.
14. Hwang S.H., Morisseau C., Do Z., Hammock B.D. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:5773-5777.
15. Hwang S.H., Tsai H.J., Liu J.Y., Morisseau C., Hammock B.D. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 2007, 50:3825-3840.
16. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002, 39:690-694.
17. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., Hammock B.D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005, 46:975-981.
18. Inceoglu B., Jinks S.L., Schmelzer K.R., Waite T., Kim I.H., Hammock B.D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006, 79:2311-2319.
19. Jones P.D., Tsai H.J., Do Z.N., Morisseau C., Hammock B.D. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 2006, 16:5212-5216.
20. Jones P.D., Wolf N.M., Morisseau C., Whetstone P., Hock B., Hammock B.D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal. Biochem. 2005, 343:66-75.
21. Jung O., Brandes R.P., Kim I.H., Schweda F., Schmidt R., Hammock B.D., Busse R., Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45:759-765.
22. Kasagami T., Kim I.H., Tsai H.J., Nishi K., Hammock B.D., Morisseau C. Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg. Med. Chem. Lett. 2009, 19:1784-1789.
23. Kim I.H., Heirtzler F.R., Morisseau C., Nishi K., Tsai H.J., Hammock B.D. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J. Med. Chem. 2005, 48:3621-3629.
24. Kim I.H., Morisseau C., Watanabe T., Hammock B.D. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 2004, 47:2110-2122.
25. Kim I.H., Nishi K., Tsai H.J., Bradford T., Koda Y., Watanabe T., Morisseau C., Blanchfield J., Toth I., Hammock B.D. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg. Med. Chem. 2007, 15:312-323.
26. Kim I.H., Tsai H.J., Nishi K., Kasagami T., Morisseau C., Hammock B.D. 1,3-Disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J. Med. Chem. 2007, 50:5217-5226.
27. Lascelles B.D., McFarland J.M., Swann H. Guidelines for safe and effective use of NSAIDs in dogs. Vet. Ther. 2005, 6:237-251.
28. Li H.Y., Jin Y., Morisseau C., Hammock B.D., Long Y.Q. The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. 2006, 14:6586-6592.
29. Li J., Carroll M.A., Chander P.N., Falck J.R., Sangras B., Stier C.T. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front. Biosci. 2008, 13:3480-3487.
30. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
31. Liu J.Y., Tsai H.J., Hwang S.H., Jones P.D., Morisseau C., Hammock B.D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br. J. Pharmacol. 2009, 156:284-296.
32. Liu Y., Zhang Y., Schmelzer K., Lee T.S., Fang X., Zhu Y., Spector A.A., Gill S., Morisseau C., Hammock B.D., Shyy J.Y. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16747-16752.
33. Loch D., Hoey A., Morisseau C., Hammock B.O., Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 2007, 47:87-98.
34. Luria A., Weldon S.M., Kabcenell A.K., Ingraham R.H., Matera D., Jiang H., Gill R., Morisseau C., Newman J.W., Hammock B.D. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 2007, 282:2891-2898.
35. Manitpisitkul P., White R.E. Whatever happened to cassette-dosing pharmacokinetics?. Drug Discov. Today 2004, 9:652-658.
36. Monti J., Fischer J., Paskas S., Heinig M., Schulz H., Gosele C., Heuser A., Fischer R., Schmidt C., Schirdewan A., Gross V., Hummel O., Maatz H., Patone G., Saar K., Vingron M., Weldon S.M., Lindpaintner K., Hammock B.D., Rohde K., Dietz R., Cook S.A., Schunck W.H., Luft F.C., Hubner N. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 2008, 40:529-537.
37. Morisseau C., Derbel M., Lane T.R., Stoutamire D., Hammock B.D. Differential induction of hepatic drug-metabolizing enzymes by fenvaleric acid in male rats. Toxicol. Sci. 1999, 52:148-153.
38. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., Hammock B.D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8849-8854.
39. Morisseau C., Hammock B.D. Measurements of Soluble Epoxide Hydrolase (sEH) Activity 2007, John Wiley & Sons, New Jersey.
40. Morisseau C., Newman J.W., Tsai H.J., Baecker P.A., Hammock B.D. Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg. Med. Chem. Lett. 2006, 16:5439-5444.
41. Newman J.W., Morisseau C., Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 2005, 44:1-51.
42. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
43. Olearczyk J.J., Quigley J.E., Mitchell B.C., Yamamoto T., Kim I.H., Newman J.W., Luria A., Hammock B.D., Imig J.D. Administration of a substituted adamantly-urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. 2009, 116:61-70.
44. Parrish A.R., Chen G., Burghardt R.C., Watanabe T., Morisseau C., Hammock B.D. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 2009, 25:217-225.
45. Schmelzer K.R., Inceoglu B., Kubala L., Kim I.H., Jinks S.L., Eiserich J.P., Hammock B.D. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13646-13651.
46. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9772-9777.
47. Sellers K.W., Sun C., Diez-Freire C., Waki H., Morisseau C., Falck J.R., Hammock B.D., Paton J.F., Raizada M.K. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J. 2005, 19:626-628.
48. Shen H.C., Ding F.X., Wang S., Deng Q., Zhang X., Chen Y., Zhou G., Xu S., Chen H.S., Tong X., Tong V., Mitra K., Kumar S., Tsai C., Stevenson A.S., Pai L.Y., Alonso-Galicia M., Chen X., Soisson S.M., Roy S., Zhang B., Tata J.R., Berger J.P., Colletti S.L. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J. Med. Chem. 2009, 52(16):5009-5012.
49. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2186-2191.
50. Smythe C.M., Heinemann H.O., Bradley S.E. Estimated hepatic blood flow in the dog; effect of ethyl alcohol on it, renal blood flow, cardiac output and arterial pressure. Am. J. Physiol. 1953, 172:737-742.
51. Spector A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 2008, 50:S52-S56.
52. Taketani M., Shii M., Ohura K., Ninomiya S., Imai T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci. 2007, 81:924-932.
53. Tibbitts J. Issues related to the use of canines in toxicologic pathology-issues with pharmacokinetics and metabolism. Toxicol. Pathol. 2003, 31(Suppl.):17-24.
54. Ulu A., Davis B.B., Tsai H.J., Kim I.H., Morisseau C., Inceoglu B., Fiehn O., Hammock B.D., Weiss R.H. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J. Cardiovasc. Pharmacol. 2008, 52:314-323.
55. Watanabe T., Schulz D., Morisseau C., Hammock B.D. High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal. Chim. Acta 2006, 559:37-44.
56. White R.E., Manitpisitkul P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab. Dispos. 2001, 29:957-966.
57. Wixtrom R.N., Silva M.H., Hammock B.D. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. Anal. Biochem. 1988, 169:71-80.
58. Wolf N.M., Morisseau C., Jones P.D., Hock B., Hammock B.D. Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Anal. Biochem. 2006, 355:71-80.
59. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., Davis B.B., Low R., Hammock B.D., Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18733-18738.
60. Zhang W., Koerner I.P., Noppens R., Grafe M., Tsai H.J., Morisseau C., Luria A., Hammock B.D., Falck J.R., Alkayed N.J. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 2007, 27:1931-1940.
61. Zhang W., Koerner I.P., Noppens R., Grafe M., Tsai H.J., Morisseau C., Luria A., Hammock B.D., Falck J.R., Alkayed N.J. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 2007.
62. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., Imig J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 2004, 15:1244-1253.